Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (DBCOND0152726)

Identifiers

Synonyms

Hormone Sensitive Metastatic Prostate Cancer / Metastatic Hormone Sensitive Prostate Cancer / Metastatic Hormone-sensitive Prostate Cancer

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Abiraterone	An antiandrogen used in the treatment of metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.	Steroid 17-alpha-hydroxylase/17,20 lyasetarget Albumincarrier Alpha-1-acid glycoprotein 1carrier Cytochrome P450 3A4enzyme Sulfotransferase 2A1enzyme Multidrug resistance-associated protein 1transporter Cytochrome P450 2D6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2C9enzyme Cytochrome P450 3A5enzyme Solute carrier organic anion transporter family member 1B1transporter
Apalutamide	An androgen receptor inhibitor used to treat non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer.	Androgen receptortarget Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2C9enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier family 22 member 2transporter Organic anion transporter 3transporter Multidrug and toxin extrusion protein 2transporter GABA(A) Receptortarget Multidrug and toxin extrusion protein 1transporter Albumincarrier
Darolutamide	An androgen receptor antagonist used for castration-resistant, non-metastatic prostate cancer and metastatic hormone-sensitive prostate cancer.	Cytochrome P450 3A4enzyme UDP-glucuronosyltransferase 1A9enzyme Androgen receptortarget Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-dependent translocase ABCB1transporter Albumincarrier Progesterone receptortarget Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06661122	A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT06010914	A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT06312670	Combining EPI-7386 with Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer	Enzalutamide	treatment	2	recruiting
NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	Abiraterone Docetaxel Niraparib Prednisone	treatment	2	not_yet_recruiting
NCT05676203	A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients	Darolutamide Docetaxel	treatment	3	recruiting
NCT03903835	ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer	Abiraterone Apalutamide Cabazitaxel Capivasertib Carboplatin Darolutamide Docetaxel Enzalutamide Niraparib Prednisone Radium Ra 223 dichloride	treatment	3	recruiting
NCT06019676	Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients	No drug interventions	Not Available	Not Available	recruiting
NCT03899467	The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC	Proxalutamide	treatment	2	completed
NCT05649943	Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment	Apalutamide	treatment	Not Available	recruiting
NCT05683964	Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression	Apalutamide Darolutamide Enzalutamide	diagnostic	0	recruiting
NCT06479187	PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer	Flotufolastat F-18	diagnostic	4	not_yet_recruiting
NCT05956639	Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC	Rezvilutamide	treatment	3	recruiting
NCT05461261	The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer	Docetaxel Platinum Prednisolone acetate	treatment	2	recruiting
NCT04076059	An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)	Enzalutamide	treatment	3	active_not_recruiting
NCT02677896	A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)	Enzalutamide	treatment	3	completed
NCT05059236	A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.	Darolutamide	treatment	2	active_not_recruiting
NCT06334120	An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea	Darolutamide	Not Available	Not Available	recruiting
NCT05901649	A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide	Apalutamide Enzalutamide	Not Available	Not Available	recruiting
NCT06498921	An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT02799602	Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer	Darolutamide Docetaxel	treatment	3	completed
NCT03343977	Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	Docetaxel	treatment	1 / 2	withdrawn
NCT05381311	Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study	No drug interventions	Not Available	Not Available	completed
NCT00309985	Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer	Docetaxel	treatment	3	active_not_recruiting
NCT03532217	Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer	Ipilimumab Nivolumab	treatment	1	completed
NCT04934722	Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension	Enzalutamide Pembrolizumab	treatment	3	active_not_recruiting
NCT06452212	Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients	No drug interventions	Not Available	Not Available	completed
NCT06134271	Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer	Abiraterone Rezvilutamide	treatment	2	not_yet_recruiting
NCT04191096	Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)	Enzalutamide Pembrolizumab	treatment	3	active_not_recruiting
NCT03879122	A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer	Docetaxel Ipilimumab Nivolumab	treatment	2 / 3	active_not_recruiting